Investors are beginning to turn cautious on biotechnology stocks as a rapid rise in Treasury yields dents the appeal for shares of companies that are often viewed as risky all-or-nothing bets on breakthrough medical treatments.
All-or-Nothing Biotech Bets Dented by Rising Treasury Yields
Investors are beginning to turn cautious on biotechnology stocks as a rapid rise in Treasury yields dents the appeal for shares of companies that are often viewed as risky all-or-nothing bets on breakthrough medical treatments.
This article was originally published by
Bloomberg Markets
and is republished here under license.
Leave a Reply